Aliases:This biomarker is also known as:
B2M, a secreted protein belonging to the beta-2-microglobulin family, is a component of the class I major histocompatibility complex (MHC) on the surface of nearly all nucleated cells and involved in the presentation of peptide antigens to the immune system. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia. B2M is detected in serum and urine.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
B2M has been shown to be the target molecule of an antibody pool against SKOV3 ovarian cancer cells. Studies have also indicated that specific antibody of B2M can inhibit the growth of SKOV3. In addition, overexpression of B2M promotes the growth of SKOV3 cells in vitro.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. B2M alone was not a strong predictor.
No associated publications found.